Timothy Perren

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

Timothy Perren, Ann Marie Swart, Jacobus Pfisterer et al. · New England Journal of Medicine · 2011 · 2.2K citations · Full text

Medicine, Oncology, Pharmacology +11

Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial

Sean Kehoe, Jane Hook, Matthew Nankivell et al. · The Lancet · 2015 · 1.4K citations

Medicine, Oncology, Surgery +14

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

Amit M. Oza, Adrian Cook, Jacobus Pfisterer et al. · The Lancet Oncology · 2015 · 867 citations · Full text

Medicine, Gynecology, Oncology +15

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Trastuzumab-Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial

Thomas Suter, Marion Procter, Dirk J. van Veldhuisen et al. · Journal of Clinical Oncology · 2007 · 565 citations · Full text

Medicine, Cardiology, Oncology +17